Russia approves third Covid-19 vaccine "CoviVac" for domestic use

The CoviVac is transported and stored at normal fridge temperatures, of 2 to 8 degrees Celcius (35.6 to 46.4 Fahrenheit), Deputy Prime Minister Tatiana Golikova said in a government briefing in January.

Published On 2021-02-21 05:15 GMT   |   Update On 2021-02-21 05:15 GMT

New Delhi: Russia on Saturday approved a third coronavirus vaccine for domestic use, Prime Minister Mikhail Mishustin said on state TV, though large-scale clinical trials of the shot, labelled CoviVac and produced by the Chumakov Centre, have yet to begin.Russia has already approved two Covid-19 vaccines, including the Sputnik V shot, developed by Moscow's Gamaleya Institute, following a...

Login or Register to read the full article

New Delhi: Russia on Saturday approved a third coronavirus vaccine for domestic use, Prime Minister Mikhail Mishustin said on state TV, though large-scale clinical trials of the shot, labelled CoviVac and produced by the Chumakov Centre, have yet to begin.

Russia has already approved two Covid-19 vaccines, including the Sputnik V shot, developed by Moscow's Gamaleya Institute, following a similar approach of granting approval before seeing any late-stage trial results.
The preemptive approvals had raised concerns among some scientists in the West, but inoculations with those first two shots began on a mass scale in Russia only after trials were concluded and showed success.
Sputnik V was approved in August and late-stage trials began in September. Mass vaccination was launched in December, after preliminary trial results showed the vaccine to be 91.4% effective.
Since then, more than two million Russians have been vaccinated with at least the first dose of Sputnik V, Health Minister Mikhail Murashko said on Feb. 10.
Rollout of a second vaccine, developed by the Vector Institute in Novosibirsk, is beginning.
"Today, Russia is the only country to have already three vaccines against Covid-19," Prime Minister Mishustin said.
The Chumakov Centre, founded in 1955 in St Petersburg by Mikhail Chumakov, is known for its work with U.S. scientist Albert Sabin at the height of the Cold War, which led to the production of the widely-used polio vaccine.
Unlike the Sputnik V vaccine, which uses a modified harmless cold virus that tricks the body into producing antigens to help the immune system prepare for a coronavirus infection, the CoviVac vaccine is a "whole-virion" vaccine.
This means it is made of a coronavirus that has been inactivated, or stripped of its ability to replicate.
"The vaccine we have developed... reflects the whole history of Russian, as well as global, vaccine science," the Chumakov Centre's director, Aidar Ishmukhametov, said on Saturday.
The CoviVac shot is given in two doses, 14 days apart. It is transported and stored at normal fridge temperatures, of 2 to 8 degrees Celsius (35.6 to 46.4 Fahrenheit), Deputy Prime Minister Tatiana Golikova said in a government briefing in January.


Tags:    
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News